Vutrisiran

Vutrisiran, sold under the brand name Amvuttra, is a medication used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Vutrisiran, sold under the brand name Amvuttra, is a medication used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is a double stranded small interfering RNA (siRNA; also called RNA interference or RNAi therapeutic) that interferes with the expression of the transthyretin (TTR) gene.

Transthyretin is a serum protein made in the liver whose major function is transport of vitamin A and thyroxine. Rare mutations in the transthyretin gene result in accumulation of large amyloid deposits of misfolded transthyretin molecules most prominently in peripheral nerves and the heart.

Patients with hATTR typically present with polyneuropathy or autonomic dysfunction followed by cardiomyopathy which, if untreated, is fatal within 5 to 10 years. Vutrisiran was approved for medical use in the United States in June 2022, in the European Union in September 2022, and in Australia in June 2024.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1355822893 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

14 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.